Montagner Alexandra, Polizzi Arnaud, Fouché Edwin, Ducheix Simon, Lippi Yannick, Lasserre Frédéric, Barquissau Valentin, Régnier Marion, Lukowicz Céline, Benhamed Fadila, Iroz Alison, Bertrand-Michel Justine, Al Saati Talal, Cano Patricia, Mselli-Lakhal Laila, Mithieux Gilles, Rajas Fabienne, Lagarrigue Sandrine, Pineau Thierry, Loiseau Nicolas, Postic Catherine, Langin Dominique, Wahli Walter, Guillou Hervé
INRA UMR1331, ToxAlim, University of Toulouse, Toulouse, France.
INSERM UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France University of Toulouse, UMR1048, Paul Sabatier University, France.
Gut. 2016 Jul;65(7):1202-14. doi: 10.1136/gutjnl-2015-310798. Epub 2016 Feb 1.
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor expressed in tissues with high oxidative activity that plays a central role in metabolism. In this work, we investigated the effect of hepatocyte PPARα on non-alcoholic fatty liver disease (NAFLD).
We constructed a novel hepatocyte-specific PPARα knockout (Pparα(hep-/-)) mouse model. Using this novel model, we performed transcriptomic analysis following fenofibrate treatment. Next, we investigated which physiological challenges impact on PPARα. Moreover, we measured the contribution of hepatocytic PPARα activity to whole-body metabolism and fibroblast growth factor 21 production during fasting. Finally, we determined the influence of hepatocyte-specific PPARα deficiency in different models of steatosis and during ageing.
Hepatocyte PPARα deletion impaired fatty acid catabolism, resulting in hepatic lipid accumulation during fasting and in two preclinical models of steatosis. Fasting mice showed acute PPARα-dependent hepatocyte activity during early night, with correspondingly increased circulating free fatty acids, which could be further stimulated by adipocyte lipolysis. Fasting led to mild hypoglycaemia and hypothermia in Pparα(hep-/-) mice when compared with Pparα(-/-) mice implying a role of PPARα activity in non-hepatic tissues. In agreement with this observation, Pparα(-/-) mice became overweight during ageing while Pparα(hep-/-) remained lean. However, like Pparα(-/-) mice, Pparα(hep-/-) fed a standard diet developed hepatic steatosis in ageing.
Altogether, these findings underscore the potential of hepatocyte PPARα as a drug target for NAFLD.
过氧化物酶体增殖物激活受体α(PPARα)是一种在具有高氧化活性的组织中表达的核受体,在新陈代谢中起核心作用。在本研究中,我们调查了肝细胞PPARα对非酒精性脂肪性肝病(NAFLD)的影响。
我们构建了一种新型的肝细胞特异性PPARα基因敲除(Pparα(hep-/-))小鼠模型。利用这个新模型,我们在非诺贝特治疗后进行了转录组分析。接下来,我们研究了哪些生理挑战会影响PPARα。此外,我们测量了空腹期间肝细胞PPARα活性对全身代谢和成纤维细胞生长因子21产生的贡献。最后,我们确定了肝细胞特异性PPARα缺陷在不同脂肪变性模型和衰老过程中的影响。
肝细胞PPARα缺失损害了脂肪酸分解代谢,导致空腹期间以及两种脂肪变性临床前模型中肝脏脂质积累。空腹小鼠在夜间早期表现出急性PPARα依赖性肝细胞活性,循环游离脂肪酸相应增加,脂肪细胞脂解可进一步刺激这种增加。与Pparα(-/-)小鼠相比,空腹导致Pparα(hep-/-)小鼠出现轻度低血糖和体温过低,这意味着PPARα活性在非肝组织中发挥作用。与这一观察结果一致,Pparα(-/-)小鼠在衰老过程中体重增加,而Pparα(hep-/-)小鼠保持消瘦。然而,与Pparα(-/-)小鼠一样,喂食标准饮食的Pparα(hep-/-)小鼠在衰老过程中也会出现肝脏脂肪变性。
总之,这些发现强调了肝细胞PPARα作为NAFLD药物靶点的潜力。